IFT88

Across TCGA pan-cancer cohorts, IFT88 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated IFT88 data layer compared with 25 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher IFT88 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated IFT88 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

LSCC, HNSC, and PDAC are the cancer types where IFT88 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Tertile	II,III,IV	0.768	1.000	<.001	35	view →
HNSC	DFS	Median	All	0.653	0.876	.004	13	view →
PDAC	OS	Median	III,IV	0.841	0.669	.008	10	view →
UCEC	OS	Tertile	II,III,IV	0.568	1.000	.031	4	view →
GBM	OS	Quartile	All	0.697	0.904	.005	4	view →
LUAD	OS	Quartile	All	0.904	0.703	.049	2	view →
CCRCC	DFS	Median	II,III,IV	0.806	0.346	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

IFT88–LSCC (DFS)

Open the LSCC breakdown →